>>The inability to be incorporated into this ultrasimple dosing is what sank Avexa's apricitabine, which was otherwise a better agent on its own than other nucleosides currently in use...
might want to take another look at Avexa' apricitabine, srgc
65% of those on hiv treatment are resistant to those frontline, single pill, expensive ($11B, lol) treatments...
Avexa's apricitabine will partner, make it to a large market and sell plenty as a result...
AND resistance may well be the reason BIT makes it to market, in quite a few years and $, lol, behind the current wave of antivirals...
clearing reservoirs? hmmm, not much evidence, yet...???
atb
BIT Price at posting:
13.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)